Umbilical cord cells may treat arthritis

Umbilical cord stem cells may be useful in the treatment of rheumatoid arthritis (RA). Animal and in vitro experiments, described in BioMed Central's open access journal Arthritis Research and Therapy, have shown that mesenchymal stem cells (MSCs) taken from umbilical cord blood can suppress inflammation and attenuate collagen-induced arthritis.

Professor Zhan-guo Li worked with a team of researchers, from Peking University People's Hospital, China, to carry out the study. He said, "Very little is known about umbilical cord MSCs, and there has been no previous report about their use in the treatment of RA. MSCs can exert profound immunosuppression, which encourages their use in the treatment of autoimmune diseases, such as RA. At present, the most common source of MSCs has been bone marrow. However, aspirating bone marrow is an invasive procedure and the number and the differentiating potential of bone marrow MSCs decrease with age. In contrast, the collection of umbilical cord MSCs does not require any invasive procedure".

The researchers took immune cells from RA patients and showed that the umbilical MSCs were able to suppress the cells' proliferation, invasive behavior and inflammatory responses. Systemic infusion of the umbilical MSCs into mice was shown to significantly reduce the severity of collagen-induced arthritis. Speaking about the results, Professor Li said, "RA imparts a massive burden on health services worldwide and none of the currently used agents reaches long term drug-free remission. Therefore, a new and more effective therapy for RA will be very welcome".

1. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis
Yanying Liu, Rong Mu, Shiyao Wang, Li Long, Xia Liu, Ru Li, Jian Sun, Jianping Guo, Xiaoping Zhang, Jing Guo, Ping Yu, Chunlei Li, Xiangyuan Liu, Zhenyu Huang, Dapeng Wang, Hu Li, Zhifeng Gu, Bing Liu and Zhanguo Li
Arthritis Research & Therapy (in press)

During embargo, article available here: http://arthritis-research.com/imedia/3138842735716890_article.pdf?random=984291

After the embargo, article available at the journal website: http://arthritis-research.com/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication.

2. Arthritis Research & Therapy is an international, peer-reviewed online journal, publishing original research, reviews, commentaries and reports. The major focus of the journal is on cellular and molecular mechanisms of arthritis, musculoskeletal conditions and systemic autoimmune rheumatic diseases and translation of this knowledge into advances in clinical care. Original basic, translational laboratory and clinical research is considered for publication along with results of therapeutic trials.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.